NEW YORK (GenomeWeb) – Atum and Horizon Discovery announced today that they have signed a cross-licensing agreement for their respective cell line production technologies.
Under the terms of the deal, Atum — formerly DNA2.0 — has been given a license to Horizon's CHO Source biomanufacturing platform, including the glutamine synthetase (GS) knockout CHO K1 line, which it will combine with its own Leap-In transposase technology as a cell line development service. Horizon, meanwhile, has been given an exclusive license to a vector suite developed by Atum for the CHO Source platform. Horizon customers will also be offered a no-fee evaluation license for the Leap-In system.
Additional terms were not disclosed.
"Horizon's GS line and Atum's vectors and transposase technology are a very powerful combination for production of stable cell lines," Atum Cofounder and CEO Jeremy Minshull said in a statement. "This technology is suited not just for regular antibodies, but for the next wave of biologics including two, three, and four-chain bispecifics, and require only small numbers of clones to be screened to reach commercial titers."